Related Experiment Videos
The effect of actinomycin D on hemopoiesis. I. Short-term effects
Abstract:
The effect of in vivo administration of actinomycin D (Act D) on the hemopoietic precursor compartments and, in particular, the BFU-E, CFU-E, and erythroblast populations was investigated over a 6-day period. Daily injections of mice with 15 microgram/kg, 30 microgram/kg, and 60 microgram/kg Act D showed a dose-dependent effect. The highest dose caused an almost complete eradication of CFU-E as well as the morphologically identifiable erythroblasts. There was no appreciable reduction in BFU-E, GM-CFU, and CFU-S. These observation indicate that Act D interferes with erythropoiesis by selectively inhibiting the CFU-E compartment. The effects are not due to altered sensitivity to erythropoietin as dose response curves were similar for control and Act D-treated cells. Although a considerable reduction in CFU-E is observed and approximately 20-30% of nucleated cells are lost from the small size region, there is no displacement in the velocity sedimentation profiles either from the remaining CFU-E and nucleated cell populations or the BFU-E and GM-CFU populations.
Insights
Actinomycin D (Act D) selectively inhibits erythropoiesis by targeting colony-forming unit-erythroid (CFU-E) cells in mice. This drug eradicates CFU-E and erythroblasts but spares earlier hematopoietic stem cells.
Area of Science:
- Hematology
- Pharmacology
- Cell Biology
Background:
- Hematopoiesis involves distinct precursor compartments.
- Erythropoiesis is a critical process regulated by specific cell populations.
- Actinomycin D (Act D) is a known inhibitor of transcription.
Purpose of the Study:
- To investigate the in vivo effects of Actinomycin D on hematopoietic precursor compartments.
- To determine the specific impact of Act D on erythropoietic progenitor cells, including BFU-E and CFU-E.
- To elucidate the mechanism by which Act D affects erythropoiesis.
Main Methods:
- Daily administration of varying doses of Act D (15, 30, 60 microgram/kg) to mice over a 6-day period.
- Analysis of hemopoietic precursor compartments, focusing on BFU-E (burst-forming unit-erythroid), CFU-E (colony-forming unit-erythroid), and erythroblasts.
- Evaluation of cell sensitivity to erythropoietin and velocity sedimentation profiles.
Main Results:
- Act D demonstrated a dose-dependent effect on erythropoiesis.
- The highest dose of Act D led to near-complete eradication of CFU-E and erythroblasts.
- No significant reduction was observed in BFU-E, GM-CFU (granulocyte-macrophage colony-forming unit), or CFU-S (colony-forming unit-spleen).
- Act D's effects were not attributed to altered erythropoietin sensitivity.
- Velocity sedimentation profiles remained unchanged, indicating no population displacement.
Conclusions:
- Actinomycin D selectively inhibits erythropoiesis by targeting the CFU-E compartment.
- The drug's primary action is on later stages of erythroid differentiation.
- CFU-E represents a critical target for Act D's anti-erythropoietic effects.